
Stephen D. Rosasco
Examiner (ID: 4235, Phone: (571)272-1389 , Office: P/1721 )
| Most Active Art Unit | 1756 |
| Art Unit(s) | 1507, 1795, 1721, 1752, 1737, 1756, 1113 |
| Total Applications | 2769 |
| Issued Applications | 2461 |
| Pending Applications | 68 |
| Abandoned Applications | 246 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17930234
[patent_doc_number] => 20220325359
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => NON-CODING RNA FOR DETECTION OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/722051
[patent_app_country] => US
[patent_app_date] => 2022-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26770
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17722051
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/722051 | NON-CODING RNA FOR DETECTION OF CANCER | Apr 14, 2022 | Abandoned |
Array
(
[id] => 18955204
[patent_doc_number] => 20240043531
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/024471
[patent_app_country] => US
[patent_app_date] => 2022-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22170
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 1671
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024471
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/024471 | ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF | Apr 13, 2022 | Pending |
Array
(
[id] => 17750856
[patent_doc_number] => 20220229061
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => DETECTION OF DESMOGLEIN-2 IN CANCERS OF EPITHELIAL ORIGIN
[patent_app_type] => utility
[patent_app_number] => 17/715092
[patent_app_country] => US
[patent_app_date] => 2022-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7908
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17715092
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/715092 | DETECTION OF DESMOGLEIN-2 IN CANCERS OF EPITHELIAL ORIGIN | Apr 6, 2022 | Pending |
Array
(
[id] => 19339322
[patent_doc_number] => 12049500
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-30
[patent_title] => Anti-nectin-4-antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/263430
[patent_app_country] => US
[patent_app_date] => 2022-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 26
[patent_no_of_words] => 11192
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18263430
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/263430 | Anti-nectin-4-antibodies and uses thereof | Mar 30, 2022 | Issued |
Array
(
[id] => 17961355
[patent_doc_number] => 20220341936
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => PD-L1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER
[patent_app_type] => utility
[patent_app_number] => 17/657537
[patent_app_country] => US
[patent_app_date] => 2022-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 94141
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17657537
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/657537 | PD-L1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | Mar 30, 2022 | Pending |
Array
(
[id] => 17929856
[patent_doc_number] => 20220324981
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => DOSING FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/704878
[patent_app_country] => US
[patent_app_date] => 2022-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 90616
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17704878
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/704878 | DOSING FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES | Mar 24, 2022 | Pending |
Array
(
[id] => 17837789
[patent_doc_number] => 20220275094
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
[patent_app_type] => utility
[patent_app_number] => 17/654801
[patent_app_country] => US
[patent_app_date] => 2022-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12199
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17654801
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/654801 | Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | Mar 13, 2022 | Issued |
Array
(
[id] => 17867112
[patent_doc_number] => 20220289847
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => METHODS FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/690634
[patent_app_country] => US
[patent_app_date] => 2022-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30139
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17690634
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/690634 | METHODS FOR THE TREATMENT OF CANCER | Mar 8, 2022 | Abandoned |
Array
(
[id] => 19186301
[patent_doc_number] => 20240165214
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => COMPOSITIONS AND METHODS FOR STABILIZATION OF ALLOSTERIC PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/547644
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30136
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18547644
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/547644 | COMPOSITIONS AND METHODS FOR STABILIZATION OF ALLOSTERIC PROTEINS | Feb 24, 2022 | Pending |
Array
(
[id] => 17807839
[patent_doc_number] => 20220259674
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 17/674121
[patent_app_country] => US
[patent_app_date] => 2022-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25183
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674121
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/674121 | COMPOSITIONS AND METHODS FOR TREATING BREAST CANCER | Feb 16, 2022 | Issued |
Array
(
[id] => 17792575
[patent_doc_number] => 20220251666
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => MUTANT CALRETICULIN FOR THE DIAGNOSIS OF MYELOID MALIGNANCIES
[patent_app_type] => utility
[patent_app_number] => 17/673686
[patent_app_country] => US
[patent_app_date] => 2022-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 99914
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17673686
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/673686 | MUTANT CALRETICULIN FOR THE DIAGNOSIS OF MYELOID MALIGNANCIES | Feb 15, 2022 | Pending |
Array
(
[id] => 19505226
[patent_doc_number] => 12116638
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-15
[patent_title] => Estrogen receptor mutations and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/673718
[patent_app_country] => US
[patent_app_date] => 2022-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 47573
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 150
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17673718
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/673718 | Estrogen receptor mutations and uses thereof | Feb 15, 2022 | Issued |
Array
(
[id] => 17625839
[patent_doc_number] => 20220160854
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => COMPOSITION AND PROCESS FOR PREPARING VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/650360
[patent_app_country] => US
[patent_app_date] => 2022-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70635
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17650360
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/650360 | COMPOSITION AND PROCESS FOR PREPARING VACCINE | Feb 7, 2022 | Abandoned |
Array
(
[id] => 17807838
[patent_doc_number] => 20220259673
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => METHODS FOR IDENTIFYING AND TREATING HIGH-PLASTICITY CELL STATE DRIVING TUMOR PROGRESSION IN LUNG CANCER
[patent_app_type] => utility
[patent_app_number] => 17/666999
[patent_app_country] => US
[patent_app_date] => 2022-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16482
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17666999
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/666999 | METHODS FOR IDENTIFYING AND TREATING HIGH-PLASTICITY CELL STATE DRIVING TUMOR PROGRESSION IN LUNG CANCER | Feb 7, 2022 | Pending |
Array
(
[id] => 18916735
[patent_doc_number] => 11879005
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-23
[patent_title] => Hetero-dimeric multi-specific antibody format
[patent_app_type] => utility
[patent_app_number] => 17/588262
[patent_app_country] => US
[patent_app_date] => 2022-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 27
[patent_no_of_words] => 10384
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 352
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17588262
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/588262 | Hetero-dimeric multi-specific antibody format | Jan 28, 2022 | Issued |
Array
(
[id] => 18013325
[patent_doc_number] => 11505607
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-22
[patent_title] => Bispecific single-chain antibody, recombinant oncolytic virus for expressing same and virus composition
[patent_app_type] => utility
[patent_app_number] => 17/568738
[patent_app_country] => US
[patent_app_date] => 2022-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 18
[patent_no_of_words] => 4505
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17568738
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/568738 | Bispecific single-chain antibody, recombinant oncolytic virus for expressing same and virus composition | Jan 4, 2022 | Issued |
Array
(
[id] => 19032533
[patent_doc_number] => 20240082348
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => COMPOSITION OF BL-8040
[patent_app_type] => utility
[patent_app_number] => 18/270521
[patent_app_country] => US
[patent_app_date] => 2021-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23386
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18270521
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/270521 | Composition of BL-8040 | Dec 28, 2021 | Issued |
Array
(
[id] => 17534702
[patent_doc_number] => 20220113311
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-14
[patent_title] => Methods of Detecting and Treating a Tumor Expressing PT346 PDK1
[patent_app_type] => utility
[patent_app_number] => 17/561042
[patent_app_country] => US
[patent_app_date] => 2021-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19411
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17561042
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/561042 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | Dec 22, 2021 | Abandoned |
Array
(
[id] => 19354115
[patent_doc_number] => 12054545
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-06
[patent_title] => Heterodimeric antibodies that bind somatostatin receptor 2
[patent_app_type] => utility
[patent_app_number] => 17/542341
[patent_app_country] => US
[patent_app_date] => 2021-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 135
[patent_figures_cnt] => 144
[patent_no_of_words] => 33464
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542341
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/542341 | Heterodimeric antibodies that bind somatostatin receptor 2 | Dec 2, 2021 | Issued |
Array
(
[id] => 19076530
[patent_doc_number] => 11945880
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-02
[patent_title] => Heterodimeric antibodies that bind CD3 and tumor antigens
[patent_app_type] => utility
[patent_app_number] => 17/542342
[patent_app_country] => US
[patent_app_date] => 2021-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 204
[patent_figures_cnt] => 212
[patent_no_of_words] => 28446
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 347
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542342
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/542342 | Heterodimeric antibodies that bind CD3 and tumor antigens | Dec 2, 2021 | Issued |